HEALTH AND ECONOMIC IMPACT OF 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV15) SEROTYPES IN ADULTS 65 YEARS AND OLDER IN CANADA
The objective of this study is to quantify the epidemiologic and economic burden of pneumococcal disease attributable to 15-valent pneumococcal conjugate vaccine (PCV15) serotypes in Canada.
A published Markov model was adapted to estimate the burden of PCV15 serotypes in a cohort of unvaccinated Canadian adults aged 65 and older who were tracked from 2015 until death. The Markov model included the following health states: no pneumococcal disease, invasive pneumococcal diseases (IPD), non-bacteremic pneumococcal pneumonia (NBPP) and death. Economic burden was estimated from a publicly funded health care payer perspective, by multiplying the number of inpatient/outpatient visits by the cost per inpatient/outpatient visits.
The model resulted in an estimated 7,834 cases of IPD and 110,372 cases of NBPP hospitalizations. Of these, there were 1,684 cases of IPD related deaths and 8,444 cases of NBPP related death. Total lifetime discounted healthcare costs attributable to PCV15 serotypes were estimated to be approximately $874.6 million. 38.5% of these costs ($337.1 million) were attributable to serotypes 22F and 33F and 22.2% were attributable to serotype 3.
The serotypes included in PCV15 contribute considerably to the health and economic burden of pneumococcal disease among older adults in Canada.